Skip to content

Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical Cystectomy

Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical Cystectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05822518
Enrollment
42
Registered
2023-04-20
Start date
2022-06-01
Completion date
2024-02-01
Last updated
2024-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Bladder, Cystostomy; Complications

Keywords

radical cystectomy, complications, immune-nutrition, immune enhancing nutrition, bladder cancer, muscle invasive bladder cancer

Brief summary

The aim of this study is to evaluate the outcome of perioperative immune-nutrition with glutamine, arginine and fish oil in patients undergoing radical cystectomy as regards to enhancement of healing, increasing immunity and improving overall health status.

Interventions

DIETARY_SUPPLEMENTNeo-mune powder (otsuka pharmaceutical)

* Preoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 3 days. * Postoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 2 weeks starting when the intestinal sounds are audible.

DRUGDipeptiven solution (Fresenius Kabi pharmaceutical)

Dipeptiven (Fresenius Kabi pharmaceutical) solution 50 mg o.d IV ( contains L-ananyl-L-glutamine dipeptide) post operatively for 5 days starting from the operation day.

Sponsors

Menoufia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patients with CT showing bladder mass with radiological staging of T2 or T3. 2. Patients pathologically proven to have cancer bladder. 3. Patients undergoing radical cystectomy with ileal conduit. 4. The American Society of Anesthesiologists Physical Status classification system (ASA PS) of 1, 2 or 3.

Exclusion criteria

1. Coagulopathy. 2. Distant metastasis. 3. Body mass index less than 18.5. 4. Relevant food allergies. 5. Severe renal and hepatic insufficiency.

Design outcomes

Primary

MeasureTime frameDescription
Postoperative complications30 daysThe number of postoperative complications, either infectious or non-infectious. Postoperative complications will be assessed and classified according to modified Clavien-Dindo classification. It consists of 7 grades (I, II, IIIa, IIIb, IVa, IVb and V) in which grade I represents the least severe complications and grade V represents the most severe complications.
Wound healing30 daysThe number of properly healed wounds. wound healing will be assessed by Pressure Ulcer Scale for Healing (PUSH) tool. this tool give every wound a score depending on surface area, exudate amount and tissue type. the scoring system ranging from 0 to 17 in which 0 represents completely healed wound and 17 represents the least healed wound. Surgical wounds are acute wounds that closure expected timeframe is about 4 weeks.
infectious complications30 daysinfection rate will be assessed by need for intervention or prescription of non-prophylactic antibiotics or presence of systemic inflammatory response syndrome (SIRS).

Secondary

MeasureTime frameDescription
Length of ICU stay30 dayswill be measured by number of days of ICU stay.
Length of hospital stay30 dayswill be measured by number of days of hospital stay.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026